Cargando…
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%–30%. There is an urgent need to optimize induction therapy by i...
Autores principales: | Bodiford, Andrew, Bodge, Megan, Talbott, Mahsa S, Reddy, Nishitha M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216035/ https://www.ncbi.nlm.nih.gov/pubmed/25368524 http://dx.doi.org/10.2147/OTT.S59269 |
Ejemplares similares
-
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016) -
Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018) -
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015) -
Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
por: Reimer, Peter, et al.
Publicado: (2013) -
Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
por: Camus, Vincent, et al.
Publicado: (2023)